Showing results (21-30 of 35) with videos related to
Sort By:
Pageof 4
Blood Advances|October 12, 2021
Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registryCharles Bowers, Daniel T Mytych, Tatiana Lawrence, et al.Bioanalysis|October 13, 2017
Assay signal as an alternative to titer for assessment of magnitude of an antidrug antibody responseMarta Starcevic Manning, Mark A Kroenke, Stephanie A Lee, et al.Clinical Pharmacology in Drug Development|February 5, 2026
Pharmacokinetic Comparability of ABP 654, a Biosimilar to Ustekinumab, Administered Either via Prefilled Syringe or Autoinjector in Healthy Adults: Results from a Randomized, Open-Label, Parallel-Group StudyVincent Chow, Peter J Winkle, Daniel T Mytych, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 22, 2007
Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumabJames A Lofgren, Sripriya Dhandapani, Jason J Pennucci, et al.Cephalalgia : an International Journal of Headache|March 11, 2022
Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensionsYanchen Zhou, Feng Zhang, Marta Starcevic Manning, et al.American Journal of Hematology|August 22, 2024
Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuriaAustin Kulasekararaj, Francesco Lanza, Alexandros Arvanitakis, et al.Journal of Immunological Methods|May 29, 2012
Development and characterization of a human antibody reference panel against erythropoietin suitable for the standardization of ESA immunogenicity testingDaniel T Mytych, Troy E Barger, Chadwick King, et al.Regulatory Toxicology and Pharmacology : RTP|February 26, 2014
The T-cell-dependent antibody response assay in nonclinical studies of pharmaceuticals and chemicals: study design, data analysis, interpretationHervé Lebrec, Brigitte Molinier, Darrell Boverhof, et al.Frontiers in Immunology|November 9, 2023
Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapyHweixian Leong Penny, Kelly Hainline, Nathaniel Theoharis, et al.Frontiers in Immunology|February 12, 2024
Translatability of findings from cynomolgus monkey to human suggests a mechanistic role for IL-21 in promoting immunogenicity to an anti-PD-1/IL-21 mutein fusion proteinMark A Kroenke, Marta Starcevic Manning, Christina L Zuch de Zafra, et al.Pageof 4